A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...

Beata Halassy, an expert infectious disease researcher, treated her own stage 3 breast cancer by injecting the tumour with ...

ADCs, including the widely used cancer drug Enhertu (trastuzumab deruxtecan), represent a new wave of targeted therapies.

Researchers from the George Washington University and the Washington DC Veterans Affairs Medical Center have published a case ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Barbara O’Brien, MD, discussed findings and implications from the phase 2 TBCRC049 study evaluating the combination of ...

A combination of two HER2-targeted drugs, tucatinib (Tukysa) and trastuzumab emtansine (Kadcyla, T-DM1), extended progression-free survival among patients with unresectable locally advanced or ...

Drugs that target advanced breast cancer could help patients with a rare cancer that affects parts of the digestive system, a ...

After chemotherapy failure, if the cancer is also resistant to endocrine therapy, patients face a double obstacle: few ...

Sarah Sammons, MD, discusses findings from an analysis of the DESTINY-Breast03 trial regarding trastuzumab deruxtecan vs ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being ...

The primary objective of the present study was to assess the anti-tumor activity of a combination of trastuzumab with carboplatin and paclitaxel in patients with recurrent or refractory ovarian ...